Precipio
Logotype for Precipio Inc

Precipio (PRPO) investor relations material

Precipio Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Precipio Inc
Q3 2026 earnings summary10 Nov, 2026

Executive summary

  • Q3 net sales reached a record $7.331M, up 8% YoY; adjusted EBITDA was $0.4M, operating cash flow was $0.6M, and quarter-end cash was $3.576M.

  • Management targets a combined annualized exit run rate above $40M at end-2027, while filings state substantial doubt remains about continued operations over the next 12 months.

Financial highlights

  • Q3 net sales were $7.331M versus $6.767M YoY; nine-month sales were $21.063M versus $17.350M.

  • Q3 gross profit was $3.378M versus $3.005M YoY; operating expenses were $3.376M versus $3.066M. Nine-month expenses rose to $11.264M from $9.318M.

  • Q3 operating income was $2K and net loss was $8K; nine-month operating loss was $2.025M and net loss was $1.670M.

  • Adjusted EBITDA was $0.4M, consistent with Q2; operating cash flow was $0.6M versus $0.7M in Q2. Cash rose $0.5M in Q3 to $3.576M.

Outlook and guidance

  • End-2027 annualized exit run-rate targets are Products above $10M, Pathology Services ~$30M, and combined above $40M; these are not FY revenue forecasts.

  • Management said the current product pipeline could support the $10M target if half converts; customer onboarding can take 3–18 months. Quarterly product revenue additions are targeted to rise from ~$100K to $250K–$500K.

  • 2027 plans include doubling the four-member commercial sales force, adding marketing and technical support, and increasing conferences, clinical evidence and distributor engagement.

  • Management expects quarter-end cash to support faster product commercialization; continued operations over the next 12 months depend on business-plan execution, additional revenue and financing if needed.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Precipio earnings date

Logotype for Precipio Inc
Q4 202625 Mar, 2027
Precipio
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Precipio earnings date

Logotype for Precipio Inc
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. The company delivers liquid biopsy products for the detection of genomic biomarkers, such as cell-free DNA (cfDNA) extracted from patient blood. Its integrated liquid biopsy platform combines proprietary CFDNA extraction and enrichment technology with third party sample preparation to enable the detection of tumor-specific cfDNA in multiple end-user clinical applications. The company is also involved in development of novel diagnostic products at its laboratories in Tempe and San Diego, California. Precipio, Inc. is based in San Diego, California.